• +1 700 888 1234

  • Effingerstrasse 40 3008 Bern Switzerland

LUCE TO ACT AS A RELEVANT STAKEHOLDER IN THE BATTLE AGAINST LUNG CANCER

Lung Cancer Europe was present at the European Cancer Forum held in Brussels. Brussels, 4 December 2018 MSD, in collaboration with […]

NOVEMBER IS LUNG CANCER AWARENESS MONTH

According to Globocan 2018, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total […]

NEW GLOBOCAN STATISTICS PLACED LUNG CANCER AS THE MOST FREQUENT CANCER AND THE LEADING CAUSE OF CANCER DEATH AMONG MALES

According to tthe new statistics, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6 % of […]

#WCLC2018 CONCLUSIONS – STRATEGIES TO MAXIMIZE THE CLINICAL BENEFIT OF EGFR TKIS IN ADVANCED NSCLC

During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert […]

#WCLC2018 CONCLUSIONS – NELSON STUDY SHOWS CT SCREENING FOR NODULE VOLUME MANAGEMENT REDUCES LUNG CANCER MORTALITY BY 26 PERCENT IN MEN

During the World Congress on Lung Cancer held this year in Toronto, Canada were presented the findings of NELSON study. […]

NEW ESMO TUMOUR DNA SCALE HELPS MATCH PATIENTS WITH CANCER TO OPTIMAL TARGETED MEDICINES

A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by […]